传法国生物科技公司TheraVectys拟赴港上市 或集资数亿美元
Zhi Tong Cai Jing·2026-01-06 05:52
Group 1 - TheraVectys SA, a French biotech company, is considering an IPO in Hong Kong, potentially raising several hundred million dollars, with plans to execute as early as this year [1] - The company specializes in immunotherapy and is focused on developing lentiviral vectors for the prevention and treatment of cancer and other diseases, having been spun off from the Pasteur Institute [1] - Typically, foreign biotech companies opt for listings in Europe or the US, making a Hong Kong IPO a rare choice for non-Chinese biotech firms, amidst China's challenge to Western dominance in medical innovation [1] Group 2 - In the previous year, healthcare companies raised approximately $13 billion in the Hong Kong stock market [1]